Home   /  Find a Trial  /  See All TrialsHELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page Print
 

See All Trials

QuickViews

Match by Tumor Type:

Newly Diagnosed (Stage I-III)
Biomarker status:
 Hormone-positive (ER+ and/or PR+)
 HER2-positive (HER2+)
 Triple negative (ER-/PR-/HER2-)
Inflammatory Breast Cancer
Biomarker status:
 Hormone-positive (ER+ and/or PR+)
 HER2-positive (HER2+)
 Triple negative (ER-/PR-/HER2-)

View by Trial Type:

Treatment:

 

Non-Treatment:

see All Trials

Sort by zip code:  

 

Share

Facebook
Twitter
Twitter

 
1 trials contain the search term(s): "NCT02312622"

Etirinotecan Pegol For Brain Metastases From Breast (or Lung) Cancer

A Phase II Study of Etirinotecan Pegol (NKTR 102) in Patients With Refractory Brain Metastases and Advanced Lung Cancer or Metastatic Breast Cancer (MBC) (NCT02312622)

Summary

Pegylated irinotecan NKTR-102 is a new version of the chemotherapy drug irinotecan (Camptosar). It was designed to be more effective and have fewer side effects than the original version. This study is investigating how well pegylated irinotecan NKTR-102 works in patients with breast (or lung) cancer that has spread to the brain and has not responded to other treatment.
This is a Phase II trial